A carregar...
Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
Safinamide (SAF) is a new drug developed for the treatment of Parkinson’s disease (PD). It is a benzylamino derivative with multiple mechanisms of action and antiparkinsonian, anticonvulsant, and neuroprotective properties. SAF inhibits monoamine oxidase B and dopamine reuptake and glutamate release...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4751980/ https://ncbi.nlm.nih.gov/pubmed/26917951 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S77749 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|